

Christophe Boudesco

PhD in Immuno-Oncology



06 79 33 23 01



Christophe.boudesco@hotmail.fr



[linkedin.com/in/christophe-boudesco-28b54515a](https://www.linkedin.com/in/christophe-boudesco-28b54515a)

RESUME



PROFILE

Young PhD with 3-year experience in the field of immunity and oncology research.

Hard worker, open minded and with a great team spirit, I want to pursue my interest in the oncology field and I figured out my long term goal career is to work in a biopharmaceutical company in a leading research unit for anticancer drug discovery or preclinical research.



EDUCATION

	Diploma :	Location :
2017- 2018	6 months PhD extension with private grant <i>(Grant : Société Française Hématologie)</i>	INSERM U1231 DIJON, Team "HSP PATHIES" (C. Garrido)
2014- 2017	PhD in oncology and molecular biology	INSERM U1231 DIJON, Team "HSP PATHIES" (C. Garrido)
2013- 2014	Master's 2 Degree - Research <i>Specialty : cellular and molecular biology</i>	6 months research internship : INSERM U1231 DIJON, Team "HSP PATHIES" (C. Garrido)
2012- 2013	Master's 1 degree Research	2 months internship : INSERM U1231 DIJON, Team "HSP PATHIES" (C. Garrido)
2011- 2012	Bachelor's degree in molecular biology	UNIVERSITE BOURGOGNE - DIJON
2009- 2011	Two year technical degree	IUT Analyse biologique et biochimique, DIJON



MAIN WORK

• 2014/2018 : Novel therapeutics insights in lymphoma research

Rational and Objective : Diffuse Large B Cell Lymphoma (DLBCL) is the most common form of adult malignancies. Among well characterized subtypes, ABC-DLBCL is the most aggressive form with poor prognosis. The aim of my PhD was to study ABC-DLBCL cancer biology to discover new potent molecular target.

Findings : **Identification of a protein, HSP110, involved in lymphoma progression.** In vitro cell line modification highlights HSP110 dependence of ABC-DLBCL (siRNA, shRNA, lentivirus). Decoding the molecular mechanisms by which HSP110 sustain tumor growth : HSP110 stabilized a mutated protein in DLBCL (**Myd88**). Highlights of HSP110 expression in ABC-DLBCL patient's samples.

Publication : **HSP110 sustains chronic NF- κ B signaling in activated B cell diffuse large B cell lymphoma through MyD88 stabilization . Christophe Boudesco, Els Verhoeyen, Laurent Martin, Catherine Chassagne-Clement, Leila Salmi, Rana Mhaidly, Céline Pangault, Thierry Fest, Selim Ramla, Fabrice Jardin, Olaf-Oliver Wolz, Alexander N. R. Weber, Carmen Garrido, and Gaetan Jego**
Accepted in *Blood* the 2018/05/30.

• 2017/2018 : HSP inhibition by small molecules in ABC-DLBCL

Rational and Objectives : With the comprehension of HSP action in ABC-DLBCL, screening of small molecules library to identify potent HSP inhibitor mimicking in vitro depletion of HSP110.

Findings : **Identification of a potent HSP inhibitor able to efficiently kill ABC-DLBCL in vitro and in vivo alone or in combination with ibrutinib.**

Publication : **HSP110 and BCR pathway inhibition : promising combination to efficiently treat Activated B Cell Diffuse Large B Cell Lymphoma.**
Christophe Boudesco, [...] Carmen Garrido, and Gaetan Jego
Submitted in coming month.



CONTRIBUTING WORK

• 2017 : HSP110 amplifies colorectal cancer cell proliferation

Publication: **HSP110 promotes colorectal cancer growth through STAT3 activation.** Berthenet K, Bokhari A, Lagrange A, Marcion G, **Boudesco C**, [...]Collura A, Jego G, Garrido C.
Oncogene. 2017 Apr 20

Contribution: Help in deciphering molecular signaling (HSP110 and STAT3 physical interaction).

• 2016 : Extracellular role of HSP110 in cancer micro-environment

Publication: **Extracellular HSP110 skews macrophage polarization in colorectal cancer.** Berthenet K, **Boudesco C**, Collura A, Svrcek M, [...] Duplomb L, Duval A, Garrido C, Jego G
Oncoimmunology. 2016 Apr 22

Contribution: Help in understanding how HSP110 links TLR to modifies macrophages polarization in cancer micro-environment.

• 2017 : Cellular communication in cell motility

Publication: **Modulation of the inwardly rectifying potassium channel Kir4.1 by the pro-invasive miR-5096 in glioblastoma cells.** Thuringer D, Chanteloup G, Boucher J, Pernet N, **Boudesco C**, [...] Cronier L, Solary E, Garrido C.
Oncotarget. 2017 Jun 6

Contribution: Help in understanding how cellular junction and miRNA can induce cell motility.

For other publications, see NCBI profile : PMID: 29177673 (2018), PMID: 28352659 (2017), PMID: 25633297 (2015)



SKILLS

- **Cell biology, molecular biology , immunology technics**
(Multi parametric Flow cytometry, molecular biology (DNA / RNA extraction and analysis, ELISA, Western blot, Bioplex,) , primary cells and cell line culture, microscopy staining and analysis, Envision,...)
- **Cell line modification and engineering**
Lentiviral / Retroviral production and transduction of cell line and primary cells, Knock-in / CrisPRCAs9, shRNA
- **Animal experimentation**
(Protocol writing, Xenograft of human cells, organ/blood sampling, IP / IV injection)
- **Chemical compounds libraries screening**
(*In vitro/in vivo* testing, cell line engineering for validation of molecule screening, in vivo and in vitro pharmacology)
- **Managerial and Logistic responsibilities**
(PhD and trainees management, project report, literature search, PhD forum organization (FJC Dijon 2015-2017), Grant writing, material and biologic resources management, patent writing)
- **Data analysis and organization**
Scientific data collection and analysis, statistical analysis, scientific reports, contextualizing data with bibliography
- **English and oral and writing abilities**
Grant writing, publication writing, international congress presentations.



REFERENCES

- Carmen Garrido, HSP pathies, team director
cgarrido@u-bourgogne.fr / (33) 3 80 39 32 56
- Gaëtan Jego, associate professor
gaetan.jego@u-bourgogne.fr / (+33)03 80 39 33 45



SYMPOSIUM PRESENTATION

- AACR , Washington DC – April 2017
International symposium in oncology
- IRCI symposium, Lyon – January 2017
International symposium in immunology
- EPHE immune days - 2016
National symposium in immunity and oncology



MISCELLANEOUS

